Paeds SAQs · genetics-dysmorphology-and-metabolism
Glycogen-storage and carbohydrate metabolism disorders — formative SAQs
Formative SAQs on recognising the hepatic glycogenoses through hepatomegaly with fasting hypoglycaemia and lactic acidosis, separating Pompe disease by its cardiomyopathy and hypotonia, delivering the unifying 'prevent fasting' management with cornstarch and continuous glucose, and holding galactosaemia and hereditary fructose intolerance as the toxic-sugar disorders.
On this page & tools
Target exams
SAQ 1 (10 marks)
A six-month-old boy presents with a distended abdomen noticed by his parents, recurrent early-morning lethargy and one generalised seizure. He feeds every three to four hours and becomes clammy and irritable if a feed is delayed. Examination reveals marked hepatomegaly (liver edge 8 cm below the costal margin), a doll-like facies and growth faltering. A blood sample drawn during a symptomatic, fasted episode shows glucose 1.8 mmol/L, lactate 7.2 mmol/L, urate 0.52 mmol/L, triglycerides 9.1 mmol/L, and a pH 7.28 with a high anion gap; ketones are low. [1] [2]
a) Give the most likely diagnosis and explain how the biochemical tetrad (hypoglycaemia, lactic acidosis, hyperuricaemia, hypertriglyceridaemia with low ketones) arises from the underlying enzyme block. (3 marks) [1]
b) Outline the definitive confirmatory testing, distinguishing molecular genetic testing from a liver enzyme biopsy and stating which you would favour first and why. (2 marks) [1]
c) Detail the long-term dietary and metabolic management, including the role of uncooked cornstarch, continuous overnight glucose, fructose and galactose restriction, and the written sick-day plan. (3 marks) [1] [2]
d) Describe the long-term complications that must be actively surveyed for in this child. (2 marks) [1]
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References5Show ledgerHide ledger
- [1]Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GPA. Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr, 2002.PMID 12373584
- [2]Weinstein DA, Wolfsdorf JI Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr, 2002.PMID 12373568
- [5]Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med, 2006.PMID 16702877
- [6]Schoser B, Roberts M, Byrne BJ, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL). Lancet Neurol, 2021.PMID 34800400
- [12]Van Calcar SC, Bernstein LE, Rohr FJ, et al. A re-evaluation of life-long severe galactose restriction for the nutrition management of classic galactosemia. Mol Genet Metab, 2014.PMID 24857409